WINT News and Press, Windtree Therapeutics Inc.

Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues) Windtree would receive a payment of $700,000 from Seismic Pharmaceutical ...

Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans are originated CommLoan has streamlined the process of obtaining commercial real...

The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments include SURFAXIN ® , lyophilized lucinactant and AER...

Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada and Mexico The pure SERCA2a activators patent for acute...

Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree to acquire Titan Environmental Services, Inc. The executed agreement releases the ...

The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation for Windtree revenue generating deals in environmental services Windtree is choosin...

Issued on behalf of CEA Industries, Inc. VANCOUVER – Baystreet.ca News Commentary – Stablecoins are set to reshape the multitrillion-dollar U.S. Treasury market as Wall Street's explosive adoption of dollar-pegged digital tokens surges 22% in 2025, driv...

Windtree Therapeutics Inc. (WINT) is expected to report for Q2 2025

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim data was consistent with the profile seen in previous studies give...

Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials Cardiogenic shock is a severe presentation of heart failure and SCAI Stag...